Menu

Conferences

picture05

EGA meeting Barcelona 2009: Big Pharma must not underestimate generics

Home/Conferences | Posted 16/09/2009

Big Pharma moving into generic medicines may seem like a shrewd move, but it is not necessarily a recipe for success, Ms Francesca Bruce of Scrip News heard at the European Generic medicines Association (EGA) conference recently held in Barcelona, Spain.

EGA: Biosimilars essential for generics industry as well

Home/Conferences | Posted 01/09/2009

Would-be big generics players will have to move into biosimilars, Ms Francesca Bruce of Scrip News heard at the European Generic medicines Association (EGA) conference recently held in Barcelona, Spain.

EGA meeting Barcelona 2009: Will size matter in the generics space?

Home/Conferences | Posted 01/09/2009

The generic medicines market is getting tougher and players of all sizes will find it harder to compete, but there are opportunities for both big and small firms, Ms Francesca Bruce of Scrip News heard at the recent European Generic medicines Association annual meeting in Barcelona, Spain.

EGA meeting Barcelona 2009: commoditisation risks sustainability of generic medicines market

Home/Conferences | Posted 01/09/2009

The commoditisation of generic medicines markets could be a real threat to the sustainability of the industry, Ms Francesca Bruce of Scrip News heard at the European Generic medicines Association's (EGA) annual conference recently held in Barcelona, Spain.

Glycosylation main approval issue with biosimilars

Home/Conferences | Posted 01/09/2009

Post-translational modifications (PTMs), particularly glycosylation, will play a critical role in how biosimilars – also called follow-on biologics or biogenerics – and will eventually be approved in the US. This stated science writer Mr Angelo DePalma in Genetic Engineering & Biotechnology News of 1 February 2009.

Building trust in biosimilars main challenge of EGA

Home/Conferences | Posted 01/09/2009

So far, three types of biosimilar medicines have been approved in the EU – somatropin (human growth hormone, hGH), epoetin (erythropoietin, EPO) and filgrastim (granulocyte colony-stimulating factor, G-CSF)) – in the form of 13 marketing authorisations from various companies under many different names.

DIA EuroMeeting: EU needs automatic pricing to get generics to market

Home/Conferences | Posted 01/09/2009

“The EU needs greater regulatory capacity and automatic pricing and reimbursement to deal with the number of generics required to serve the market”, said Mr Georg Stark, Joint Managing Director of Alfred E Tiefenbacher GmbH & Co, speaking at the Drug Information Association (DIA) 21st Annual EuroMeeting held in Berlin, Germany, from 23-25 March 2009.